Severe tricuspid regurgitation in a patient receiving low-dose cabergoline for the treatment of acromegaly

Journal of Heart Valve Disease

Volumn 19, Issue 6, 2010, Pages 797-800

  Izgi, Cemil ^a   Feray, Hasan ^a   Cevik, Cihan ^c   Saltan, Yelda ^a   Mansuroglu, Denyan ^b   Nugent, Kenneth ^c  

^a Gaziosmanpasa Hospital   (Turkey)

^b Gaziosmanpasa Hospital   (Turkey)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; CABERGOLINE; FUROSEMIDE; METFORMIN; OCTREOTIDE; SOMATOSTATIN;

ACROMEGALY; ADULT; ARTICLE; CASE REPORT; DIABETES MELLITUS; DIURETIC THERAPY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; LEG EDEMA; LOW DRUG DOSE; MEDICAL HISTORY; PRIORITY JOURNAL; SYSTOLIC HEART MURMUR; TRICUSPID VALVE REGURGITATION;

ACROMEGALY; DIURETICS; ECHOCARDIOGRAPHY, DOPPLER, COLOR; ERGOLINES; FEMALE; FUROSEMIDE; HEART FAILURE; HORMONE ANTAGONISTS; HUMANS; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TRICUSPID VALVE INSUFFICIENCY;

EID: 79551501957     PISSN: 09668519     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol 2007;6:826-829 (Pubitemid 47243713)
2. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007;356:39-46 (Pubitemid 46041752)
3. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac valve regurgitation. N Engl J Med 2007;356:29-38 (Pubitemid 46041751)
4. Pritchett AM, Morrison JF, Edwards WD, Schaff HV, Connolly HM, Espinosa RE. Valvular heart disease in patients taking pergolide. Mayo Clin Proc 2002;77:1280-1286
5. Horvath J, Fross RD, Kleiner-Fisman G, et al. Severe multivalvular heart disease: A new complication of the ergot derivative dopamine agonists. Mov Disord 2004;19:656-662 (Pubitemid 39173018)
6. Pinero A, Marcos-Alberca P, Fortes J. Cabergoline-related severe restrictive mitral regurgitation. N Engl J Med 2005;353:1976-1977 (Pubitemid 41565968)
7. Kars M, Pereira AM, Bax JJ, Romijn JA. Cabergoline and cardiac valve disease in prolactinoma patients: Additional studies during long-term treatment are required. Eur J Endocrinol 2008;159:363-367
8. Colao A, Galderisi M, Di Sarno A, et al. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab 2008;93:3777-3784
9. Bogazzi F, Manetti L, Raffaelli V, Lombardi M, Rossi G, Martino E. Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: A meta-analysis from clinical studies. J Endocrinol Invest 2008;31:1119-1123
10. Cawood TJ, Bridgman P, Hunter L, Cole D. Low-dose cabergoline causing valvular heart disease in a patient treated for prolactinoma. Intern Med J 2009;39:266-267
11. Pereira AM, van Thiel SW, Lindner JR, et al. Increased prevalence of regurgitant valvular heart disease in acromegaly. J Clin Endocrinol Metab 2004;89:71-75